FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2026年3月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | H 股份類別 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) 02496 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 內幕消息 完成H股全流通 本公告由武漢友芝友生物製藥股份有限公司（「本公司」）根據香港聯合交易所有限 公司（「聯交所」）證券上市規則（「上市規則」）第13.09 (2) (a)條及證券及期貨條例（ 香 港法例第571章）第XIVA部項下內幕消息條文（ 定義見上市規則 ）而作出。 茲提述本公司日期為2025年5月12日、2026年1月26日及2026年2月4日之公告（「該 等公告」），內容有關H股全流通。除另有界定 者外，本公告所用詞彙與該等公告 所界定者具有相同涵義。 完成H股全流通 董事會欣然宣佈，於2026年3月30日完成將合共68,010,299 股非上市股份轉換為H 股，而轉換後H股將於2026年3月31日上午九時正於聯交所開始上市。 – 1 – 股權架構 WUH ...

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 66,858,000, compared to RMB 107,813,000 for the year ended December 31, 2024, representing a decrease of approximately 38%[4] - The cost of revenue for the same period was RMB 56,123,000, up from RMB 22,744,000, indicating a significant increase in costs[4] - Gross profit for the year ended December 31, 2025, was RMB 10,735,000, down from RMB 85,069,000, reflecting a decline of about 87%[4] - The company reported a net loss of RMB 84,732,000 for the year ended December 31, 2025, compared to a loss of RMB 97,599,000 in the previous year, indicating an improvement in financial performance[4] - The basic loss per share was RMB 0.44, compared to RMB 0.50 in the previous year, reflecting a slight improvement in per-share performance despite ongoing losses[88] - The total loss and comprehensive expenses for the reporting period amounted to RMB 84.7 million, a decrease of RMB 12.9 million compared to RMB 97.6 million in the same period last year, primarily due to a revenue decrease of RMB 41.0 million[48] - The company has not declared or paid any dividends for the years ended December 31, 2025, and 2024[134] Research and Development - Research and development expenses were RMB 78,198,000 for the year ended December 31, 2025, compared to RMB 164,986,000 in the previous year, showing a reduction of approximately 53%[4] - The company has made significant progress in its product pipeline, with three out of four clinical-stage candidates focused on tumor treatment or related complications[6] - The core product M701 is aimed at treating malignant ascites and malignant pleural effusion, with a partnership established for its development and commercialization[12] - The company plans to submit a Biologics License Application (BLA) for M701 in 2026, indicating a strategic move towards market entry[8] - M701 treatment for MA has completed enrollment of 312 patients in the Phase III clinical trial as of July 2025[17] - M701 treatment for MPE has completed enrollment of 92 patients in the Phase II clinical trial as of September 2025[17] - Y101D, a core product for treating solid tumors, completed Phase I clinical trials in September 2024[20] - Y332, targeting multiple solid tumors, completed Phase I clinical trials with 18 patients enrolled in February 2025[21] - Y400, an innovative biopharmaceutical for retinal neovascular diseases, has progressed to Phase II clinical trials in China, with 23 patients enrolled[23] - Y225, a biosimilar to Emicizumab for hemophilia treatment, has completed various development stages including GMP batch production[24] - M701, Y101D, Y332, Y225, and Y400 are under development with no guarantee of successful commercialization[27] Financial Position - The total non-current assets were RMB 43,107,000, while current assets were RMB 131,900,000 as of December 31, 2025[4] - Total assets as of December 31, 2025, amounted to RMB 131,900,000, while total liabilities were RMB 200,536,000, resulting in a net asset value of RMB (68,636,000)[89] - The company's total equity showed a decrease from RMB 30,535,000 in 2024 to RMB (53,029,000) in 2025, representing a negative shift in equity position[90] - As of December 31, 2025, cash and cash equivalents are expected to decrease from RMB 126.3 million as of December 31, 2024, to RMB 100.1 million, mainly due to ongoing operating losses during the reporting period[49] - Current assets as of December 31, 2025, total RMB 131.9 million, including cash and cash equivalents of RMB 100.1 million and trade and other receivables of RMB 25.6 million[50] Operational Highlights - The company maintains a production facility of approximately 1,400 square meters, capable of producing 20-24 batches annually to meet early-stage clinical trial needs[28] - The company is focused on developing bispecific antibodies for targeted therapy and tumor immunotherapy, addressing significant unmet medical needs in oncology and age-related ophthalmic diseases[92] - The company is preparing to conduct international multi-center clinical trials for M701, targeting rapid realization of overseas value[31] - The company has agreed to transfer land use rights and buildings for approximately RMB 36,880,000 on January 23, 2026[66] Governance and Compliance - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2025, and confirmed compliance with relevant accounting standards and legal regulations[84] - The company has established an audit committee to oversee financial reporting processes and internal control systems, enhancing corporate governance[83] - The board of directors includes both executive and non-executive members, ensuring diverse governance[156] Employee and Corporate Structure - As of December 31, 2025, the company has a total of 106 employees, including 83 R&D personnel and 23 general and administrative staff[73] - The company emphasizes a competitive compensation package and compliance with various government-mandated employee welfare plans, including social insurance and housing funds[74] - The company has implemented employee incentive plans to recognize contributions and promote development, including the Wuhan Talent Employee Incentive Plan[76] - The company has undergone a restructuring to become a joint-stock company, with shares listed on the Hong Kong Stock Exchange since September 25, 2023[91] Future Outlook - The company plans to accelerate the clinical development and market application of M701, with a focus on domestic and international clinical trials[31] - The company aims to deepen its R&D capabilities and explore global collaboration opportunities for early-stage projects[32] - The company is actively negotiating with banks to extend bank financing, demonstrating proactive financial management strategies[105] - The group anticipates having sufficient operating funds to meet its financial obligations over the next 15 months, based on cash flow forecasts[106]

武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司（「 本 公 司 」）董 事 會（「 董 事 會 」）兹 通 告 謹 定 於 2026年3月27日（ 星期五 ）舉行董事會會議，藉以（ 其中包括 ）考慮及批准本公司及 其 附 屬 公 司 截 至 2025 年 12 月 31 日 止 年 度 的 全 年 業 績 及 其 發 佈 ， 以 及 處 理 其 他 事 項。 承董事會命 武漢友芝友生物製藥股份有限公司 董事長、執行董事兼首席執行官 於本公告日期，董事會包括執行董事Zhou Pengfei博士及溫植成先生；非執行董事 袁謙博士、周宏峰博士、龐振海先生、惠希武博士及謝守 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢友芝友生物製藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02496 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 111,468,814 | RMB | | 1 RMB | | 111,468,814 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 111,468,814 | RMB | | 1 RMB | | 111,468,814 | | 2. 股份 ...

Product Development Progress - The company's recombinant anti-EpCAM/CD3 bispecific antibody M701 has received FDA approval for clinical trials to treat malignant pleural effusion, with II phase clinical trial data in China showing significant extension of patients' puncture-free survival time, which may act as a catalyst for stock price [2] - The clinical trial application for the biosimilar Y225, used for treating hemophilia A, has been approved by the National Medical Products Administration of China, further expanding the company's pipeline [2] Company Structure and Governance - Dr. Wang Tao, the employee representative supervisor, has resigned for personal career development reasons, with Dr. Shi Jian, the director of the Translational Medicine Department, taking over, indicating a need to monitor the stability of company governance following this personnel change [3] Financial Performance - The financial report for the first half of 2025 shows a year-on-year reduction in net loss, primarily due to increased revenue from R&D services resulting from a licensing collaboration with Zhengda Tianqing, with future commercial cooperation progress and cash flow improvements warranting attention [4] Industry Policy and Environment - Policies such as accelerated approval for innovative drugs continue to optimize, potentially boosting sentiment in the biotechnology sector; as a bispecific antibody development company, the value of its technology platform and pipeline may be reassessed during the industry's innovation cycle [5]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 補充公告 須予披露交易 轉讓土地使用權及建築物 茲提述武漢 友芝友生物製藥股份 有限公司（「本公司」）日期為 2026 年1 月23 日有關 轉讓土地使用權及建築物的公告（「該公告」）。本公告所用詞彙與該公告所界定者 具有相同涵義。 本公司謹此提供有關轉讓事項的進一步資料。 (1) 土地使用權及建築物的原定用途 然而，由於超出本集團控制範圍的原因（ 包括武漢市自然資源和規劃局延遲交 付該地塊以及新冠疫情的影響 ），建設工程遭到延誤。 – 1 – 過 去 十 年 間 ， 中 國 內 地 合 同 生 產 組 織（「 CM O 」）╱ 合 同 開 發 與 生 ...

Core Viewpoint - The company has received approval from the Stock Exchange for the listing and trading of 68.01 million H-shares, which corresponds to the total number of non-listed shares to be converted and listed [1] Group 1 - The approval date for the listing of H-shares is February 4, 2026 [1] - The total number of H-shares approved for listing is 68.01 million [1]

Core Viewpoint - The company, Youzhiyou Biotechnology-B (02496), has received approval from the Hong Kong Stock Exchange to list and trade 68.0103 million H-shares, which corresponds to the total number of non-listed shares to be converted and listed [1] Group 1 - The approval date for the listing of H-shares is February 4, 2026 [1] - The total number of H-shares approved for listing is 68.0103 million [1] - The H-shares are related to the conversion of the company's non-listed shares [1]

Core Viewpoint - The company, Youzhiyou Biotechnology-B (02496.HK), has received approval from the Hong Kong Stock Exchange for the listing and trading of 68,010,299 H shares, which corresponds to the total number of non-listed shares to be converted and listed [1] Group 1 - The approval was granted on February 4, 2026 [1] - The number of H shares approved for listing is significant, indicating potential growth and liquidity for the company [1]